Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) Assets Average (2020 - 2025)

Beam Therapeutics (BEAM) has disclosed Assets Average for 6 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • On a quarterly basis, Assets Average rose 22.73% to $1.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 billion, a 22.73% increase, with the full-year FY2025 number at $1.3 billion, up 0.84% from a year prior.
  • Assets Average was $1.4 billion for Q4 2025 at Beam Therapeutics, up from $1.4 billion in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $1.5 billion in Q1 2022 to a low of $572.5 million in Q1 2021.
  • A 5-year average of $1.3 billion and a median of $1.3 billion in 2023 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: surged 260.44% in 2021, then decreased 17.27% in 2024.
  • Beam Therapeutics' Assets Average stood at $1.3 billion in 2021, then rose by 2.32% to $1.3 billion in 2022, then grew by 2.17% to $1.4 billion in 2023, then fell by 17.27% to $1.1 billion in 2024, then increased by 22.73% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Assets Average are $1.4 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.4 billion (Q2 2025).